AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32430775 — intervention group
Group type: EXPERIMENTAL
Intervention: TePe EasyPick™ (SCIP)
Number of subjects: 30
Study 32430775 — intervention group
Group type: COMPARATOR
Intervention: TePe Interdental Brushes Original (IDB)
Number of subjects: 30
Study 35253684 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating Shiftwork Questionnaire (RSQ)
Number of subjects: 18
Study 34465476 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG antibodies against pertussis toxin (PT) measured with the CDC/FDA ELISA
Number of subjects: 1581
Study 34465476 — intervention group
Group type: COMPARATOR
Intervention: EUROIMMUN test
Number of subjects: 1581
Study 34843380 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 100
Study 34843380 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 100
Study 34843380 — intervention group
Group type: COMPARATOR
Intervention: Both SG and RYGB
Number of subjects: 100
Study 32446176 — intervention group
Group type: EXPERIMENTAL
Intervention: safinamide 50 mg/day (S50)
Number of subjects: 406
Study 32446176 — intervention group
Group type: EXPERIMENTAL
Intervention: safinamide 100 mg/day (S100)
Number of subjects: 406
Study 32446176 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 406
Study 33031517 — intervention group
Group type: EXPERIMENTAL
Intervention: V160 vaccine
Number of subjects: 0
Study 32036693 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin
Number of subjects: 20
Study 32036693 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 20
Study 34173895 — intervention group
Group type: EXPERIMENTAL
Intervention: Act Healthy (AH)
Number of subjects: 61
Study 34173895 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling (SC) plus Life-Steps medication adherence counseling
Number of subjects: 61
Study 34173895 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 61
Study 34847226 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (5 mmol of calcium chloride, n=197)
Number of subjects: 397
Study 34847226 — intervention group
Group type: COMPARATOR
Intervention: Saline (n=200)
Number of subjects: 397
Study 36219589 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention using printed message cards about the quadrivalent HPV vaccine (n = 118)
Number of subjects: 238
Study 36219589 — intervention group
Group type: COMPARATOR
Intervention: Routine instructions (Control group, n = 120)
Number of subjects: 238
Study 33797635 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly filled flowable composite Clearfil Majesty ES Flow (ES, n = 42)
Number of subjects: 27
Study 33797635 — intervention group
Group type: COMPARATOR
Intervention: Conventional paste-type composite Majesty (MJ, n = 42)
Number of subjects: 27
Study 35815478 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricalcium silicate (TCS) paste
Number of subjects: 45
Study 35815478 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein phosphopeptide amorphous calcium phosphate (CPP-ACP)
Number of subjects: 45
Study 35815478 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride potassium iodide (SDF-KI)
Number of subjects: 45
Study 35815478 — intervention group
Group type: COMPARATOR
Intervention: SDF-KI
Number of subjects: 45
Study 35815478 — intervention group
Group type: COMPARATOR
Intervention: CPP-ACP
Number of subjects: 45
Study 32419645 — intervention group
Group type: EXPERIMENTAL
Intervention: ColdZyme Mouth Spray
Number of subjects: 123
Study 32419645 — intervention group
Group type: EXPERIMENTAL
Intervention: ColdZyme Mouth Spray (good compliance)
Number of subjects: 123
Study 32419645 — intervention group
Group type: EXPERIMENTAL
Intervention: ColdZyme Mouth Spray (poor compliance)
Number of subjects: 123
Study 32419645 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 123
Study 32419645 — intervention group
Group type: EXPERIMENTAL
Intervention: ColdZyme Mouth Spray (overall)
Number of subjects: 123
Study 32419645 — intervention group
Group type: COMPARATOR
Intervention: Control (overall)
Number of subjects: 123
Study 32925811 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automatic stapler
Number of subjects: 664
Study 32925811 — intervention group
Group type: COMPARATOR
Intervention: Needle (conventional thread)
Number of subjects: 664
Study 35090529 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin and zinc co-supplementation
Number of subjects: 84
Study 35090529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 34105688 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 208
Study 34105688 — intervention group
Group type: COMPARATOR
Intervention: Group education
Number of subjects: 208
Study 34105688 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 208
Study 34898069 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic massage twice a week (Group A)
Number of subjects: 76
Study 34898069 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback and electrical stimulation 5 times a week (Group B)
Number of subjects: 76
Study 34898069 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback and electrical stimulation 5 times a week combined with prostatic massage twice a week (Group C)
Number of subjects: 76
Study 34898069 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group D)
Number of subjects: 76
Study 34337917 — intervention group
Group type: EXPERIMENTAL
Intervention: As needed propofol administration
Number of subjects: 32
Study 34337917 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of propofol (5 mg kg‐1 h‐1)
Number of subjects: 32
Study 33790049 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and tocilizumab (if necessary) in addition to optimal supportive care
Number of subjects: 172
Study 33790049 — intervention group
Group type: COMPARATOR
Intervention: Optimal supportive care only
Number of subjects: 172
Study 33315051 — intervention group
Group type: EXPERIMENTAL
Intervention: AKB‐9778 (subcutaneous treatment)
Number of subjects: 0
Study 33315051 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ocular AKB‐9778
Number of subjects: 0
Study 33315051 — intervention group
Group type: EXPERIMENTAL
Intervention: AKB‐9778 (mechanistic studies in mice)
Number of subjects: 0
Study 36147653 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine plus bupivacaine (LB+B)
Number of subjects: 89
Study 36147653 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine plus dexamethasone (R+D)
Number of subjects: 89
Study 33066972 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intravenous iron therapy
Number of subjects: 487
Study 33066972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study 35886119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-endurance running (average of 4 ± 2 ultra-trails per year)
Number of subjects: 66
Study 35886119 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-distance running practice
Number of subjects: 66
Study 34340632 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental fatigue & self‐controlled feedback (MF&SCF)
Number of subjects: 44
Study 34340632 — intervention group
Group type: COMPARATOR
Intervention: Mental fatigue & yoked feedback (MF&Y)
Number of subjects: 44
Study 34340632 — intervention group
Group type: EXPERIMENTAL
Intervention: No mental fatigue & self‐controlled feedback (NMF&SCF)
Number of subjects: 44
Study 34340632 — intervention group
Group type: COMPARATOR
Intervention: No mental fatigue & yoked feedback (NMF&Y)
Number of subjects: 44
Study 32474433 — intervention group
Group type: EXPERIMENTAL
Intervention: ICMJE-member journals with explicit data-sharing policy
Number of subjects: 200
Study 32474433 — intervention group
Group type: EXPERIMENTAL
Intervention: ICMJE-affiliated journals with explicit data-sharing policy
Number of subjects: 200
Study 32474433 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs published in ICMJE-member journals
Number of subjects: 200
Study 32474433 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs published in ICMJE-affiliated journals with explicit data-sharing policy
Number of subjects: 200
Study 35438278 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (2g 8 hourly) for five days
Number of subjects: 80
Study 35438278 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine (200 mg 12 hourly) for five days
Number of subjects: 80
Study 35438278 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Vitamin C and Thiamine for five days
Number of subjects: 80
Study 35438278 — intervention group
Group type: COMPARATOR
Intervention: Neither Vitamin C nor Thiamine (control group)
Number of subjects: 80
Study 35438278 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study 33128801 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 90
Study 33128801 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 90
Study 33128801 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 90
Study 35713933 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 73
Study 35713933 — intervention group
Group type: COMPARATOR
Intervention: Stretching-and-toning (active control)
Number of subjects: 73
Study 36397218 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion treatment (once every other day, 3 times a week for 5 weeks)
Number of subjects: 70
Study 36397218 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medication therapy (control group)
Number of subjects: 70
Study 32508339 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT) with conventional physiotherapy
Number of subjects: 11
Study 32508339 — intervention group
Group type: EXPERIMENTAL
Intervention: Early start of RAGT
Number of subjects: 11
Study 32508339 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 11
Study 32508339 — intervention group
Group type: COMPARATOR
Intervention: Late start of RAGT
Number of subjects: 11
Study 34323244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose
Number of subjects: 138
Study 34323244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 138
Study 34323244 — intervention group
Group type: EXPERIMENTAL
Intervention: Stevia
Number of subjects: 138
Study 34323244 — intervention group
Group type: COMPARATOR
Intervention: Control (Sucrose)
Number of subjects: 138
Study 36088747 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal intervention including lifestyle-related disease management, physical exercise, cognitive training, and nutritional counselling over 18 months.
Number of subjects: 200
Study 32930519 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Keraring segment implantation according to the Q-value-based nomogram (QN)
Number of subjects: 104
Study 32930519 — intervention group
Group type: COMPARATOR
Intervention: Standard manufacturer's nomogram (SN)
Number of subjects: 104
Study 32452352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (IXEQ4W)
Number of subjects: 0
Study 32452352 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every 2 weeks (ADAQ2W)
Number of subjects: 0
Study 32452352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36448974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal oxytocin (100 μg)
Number of subjects: 90
Study 36448974 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 90
Study 34315283 — intervention group
Group type: EXPERIMENTAL
Intervention: OPUS treatment after implementation
Number of subjects: 3328
Study 34315283 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 3328
Study 35182606 — intervention group
Group type: EXPERIMENTAL
Intervention: γ‐tACS of the cerebellum
Number of subjects: 22
Study 35182606 — intervention group
Group type: EXPERIMENTAL
Intervention: γ‐tACS of the SMA
Number of subjects: 22
Study 35182606 — intervention group
Group type: EXPERIMENTAL
Intervention: simultaneous stimulation of both regions
Number of subjects: 22
Study 34276366 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.5 mg/h, maximum 3 mg/h) plus albumin (20–40 g/day)
Number of subjects: 60
Study 34276366 — intervention group
Group type: COMPARATOR
Intervention: Midodrine (5 mg three times/day, maximum 12.5 mg three times/day) plus octreotide (100 μg/6 h, maximum 200 μg/6 h) plus albumin (20–40 g/day)
Number of subjects: 60
Study 35065634 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU of OXT vaginal gel daily for eight weeks
Number of subjects: 64
Study 35065634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 33858230 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (interactive videos)
Number of subjects: 38
Study 33858230 — intervention group
Group type: COMPARATOR
Intervention: Group B (summary information with web-links)
Number of subjects: 38
Study 33858230 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study 34495953 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel use
Number of subjects: 0
Study 34495953 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 0
Study 33109148 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health promotion program (biweekly group education sessions and a 12-week individual behavioral modification for oral hygiene course)
Number of subjects: 68
Study 33109148 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 68
Study 33109148 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health promotion program
Number of subjects: 68
Study 34921230 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Number of subjects: 55
Study 34921230 — intervention group
Group type: EXPERIMENTAL
Intervention: GOFL
Number of subjects: 55
Study 33105418 — intervention group
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC) oxygenation (Optiflow)
Number of subjects: 40
Study 33105418 — intervention group
Group type: COMPARATOR
Intervention: Nasal prongs
Number of subjects: 40
Study 33297458 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic
Number of subjects: 66
Study 33297458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 34825740 — intervention group
Group type: EXPERIMENTAL
Intervention: PARO robot twice a day (Group 1)
Number of subjects: 45
Study 34825740 — intervention group
Group type: EXPERIMENTAL
Intervention: PARO robot once a day (Group 2)
Number of subjects: 45
Study 34825740 — intervention group
Group type: COMPARATOR
Intervention: Plush-Toy (non-robotic PARO) once a day (Group 3)
Number of subjects: 45
Study 34825740 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Group 1, Group 2, Group 3)
Number of subjects: 45
Study 34108672 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg
Number of subjects: 17
Study 34108672 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab 600 mg
Number of subjects: 17
Study 34108672 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (both dosages)
Number of subjects: 17
Study 32513251 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab, pertuzumab, and eribulin mesylate
Number of subjects: 244
Study 32513251 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab, pertuzumab, and a taxane
Number of subjects: 244
Study 33765841 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time functional magnetic resonance imaging neurofeedback
Number of subjects: 0
Study 32108044 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - 500 µg fluticasone propionate twice daily
Number of subjects: 751
Study 32108044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 751
Study 32949568 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged wireless reflux monitoring and a 3-week PPI cessation intervention
Number of subjects: 100
Study 34143215 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular (LV) compressions
Number of subjects: 34
Study 34143215 — intervention group
Group type: COMPARATOR
Intervention: Traditional compressions
Number of subjects: 34
Study 32058435 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of daily chlorhexidine showers and mupirocin nasal ointment twice a day (for S. aureus carriers)
Number of subjects: 1318
Study 32058435 — intervention group
Group type: COMPARATOR
Intervention: Control (S. aureus carriers)
Number of subjects: 1318
Study 32058435 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of daily chlorhexidine showers and mupirocin nasal ointment twice a day (for noncarriers)
Number of subjects: 1318
Study 32058435 — intervention group
Group type: COMPARATOR
Intervention: Control (noncarriers)
Number of subjects: 1318
Study 34256038 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacopa monnieri
Number of subjects: 700000
Study 34256038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700000
Study 32978836 — intervention group
Group type: EXPERIMENTAL
Intervention: VR‐ToMIS
Number of subjects: 21
Study 32978836 — intervention group
Group type: COMPARATOR
Intervention: Passive VR
Number of subjects: 21
Study 32659714 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 83
Study 36352204 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-mg pramipexole
Number of subjects: 22
Study 36352204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 34465833 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea + Biochar (BC) (10 Mg ha-1)
Number of subjects: 5
Study 34465833 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea + Biochar (BC) + Urease Inhibitor (UI) (1 L ton-1)
Number of subjects: 5
Study 34465833 — intervention group
Group type: COMPARATOR
Intervention: Urea (150 kg N ha-1)
Number of subjects: 5
Study 34465833 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochar (BC) (10 Mg ha-1)
Number of subjects: 5
Study 34465833 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 5
Study 32755115 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-5 treatments (mepolizumab, benralizumab, reslizumab)
Number of subjects: 10
Study 34285768 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy sessions (tr‐MI, N = 39)
Number of subjects: 74
Study 34285768 — intervention group
Group type: COMPARATOR
Intervention: Psychological treatment as usual (TAU, N = 35)
Number of subjects: 74
Study 34285768 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy sessions (tr‐MI)
Number of subjects: 74
Study 34285768 — intervention group
Group type: COMPARATOR
Intervention: Psychological treatment as usual (TAU)
Number of subjects: 74
Study 32267934 — intervention group
Group type: COMPARATOR
Intervention: Triglycerides <1 mmol/L (<89 mg/dL)
Number of subjects: 108559
Study 32267934 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides 2.0-2.9 mmol/L (177-265 mg/dL)
Number of subjects: 108559
Study 32267934 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides 3.0-3.9 mmol/L (266-353 mg/dL)
Number of subjects: 108559
Study 32267934 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides 4.0-4.9 mmol/L (354-442 mg/dL)
Number of subjects: 108559
Study 32267934 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides ≥5 mmol/L (≥443 mg/dL)
Number of subjects: 108559
Study 32267934 — intervention group
Group type: COMPARATOR
Intervention: Plasma triglycerides <2.0 mmol/L (77 mg/dL)
Number of subjects: 108559
Study 32267934 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma triglycerides 2.0-4.9 mmol/L (177-442 mg/dL)
Number of subjects: 108559
Study 32267934 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma triglycerides ≥5.0 mmol/L (443 mg/dL)
Number of subjects: 108559
Study 32267934 — intervention group
Group type: COMPARATOR
Intervention: Remnant cholesterol <0.5 mmol/L (19 mg/dL)
Number of subjects: 108559
Study 32267934 — intervention group
Group type: EXPERIMENTAL
Intervention: Remnant cholesterol 0.5-1.4 mmol/L (19-57 mg/dL)
Number of subjects: 108559
Study 32267934 — intervention group
Group type: EXPERIMENTAL
Intervention: Remnant cholesterol ≥1.5 mmol/L (58 mg/dL)
Number of subjects: 108559
Study 32267934 — intervention group
Group type: COMPARATOR
Intervention: Allele score 13-16
Number of subjects: 108559
Study 32267934 — intervention group
Group type: EXPERIMENTAL
Intervention: Allele score 17-18
Number of subjects: 108559
Study 32267934 — intervention group
Group type: EXPERIMENTAL
Intervention: Allele score 19-20
Number of subjects: 108559
Study 36319912 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (20 mg in 100 mL normal saline)
Number of subjects: 73
Study 36319912 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (100 mL)
Number of subjects: 73
Study 33586474 — intervention group
Group type: EXPERIMENTAL
Intervention: Take Charge intervention (one, two, or zero sessions)
Number of subjects: 400
Study 33586474 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400
Study 33586474 — intervention group
Group type: EXPERIMENTAL
Intervention: Take Charge groups combined
Number of subjects: 400
Study 36220712 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive Immunotherapy with CD25/CD71 allodepleted donor T cells (ADTs)
Number of subjects: 21
Study 36220712 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Control)
Number of subjects: 21
Study 33205343 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 32
Study 33205343 — intervention group
Group type: COMPARATOR
Intervention: Saline injections (Control)
Number of subjects: 32
Study 32147032 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injections of 200000 IU vitamin D supplement (two injections, one at week 0 and another at week 4)
Number of subjects: 50
Study 32147032 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 50
Study 33619983 — intervention group
Group type: EXPERIMENTAL
Intervention: Splint
Number of subjects: 159
Study 33619983 — intervention group
Group type: COMPARATOR
Intervention: Splint-less
Number of subjects: 159
Study 33619983 — intervention group
Group type: EXPERIMENTAL
Intervention: Splint (preterms)
Number of subjects: 159